{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:46:34Z","timestamp":1790725594317,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,15]]},"DOI":"10.7759\/cureus.58288","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T08:45:12Z","timestamp":1713170712000},"source":"Crossref","is-referenced-by-count":7,"title":["Rituximab in Childhood and Juvenile Pemphigus Vulgaris: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Priyanshu","family":"Shrivastava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mariam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laraib","family":"Abid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajad A","family":"Buch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed A","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnaz","family":"Mansoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamimul","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01418","article-title":"Pemphigus: current and future therapeutic strategies","volume":"10","author":"Didona D","year":"2019","unstructured":"Didona D, Maglie R, Eming R, Hertl M. Pemphigus: current and future therapeutic strategies. Front Immunol. 2019, 10:1418. 10.3389\/fimmu.2019.01418","journal-title":"Front Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.895490","article-title":"Clinical patterns, survival, comorbidities, and treatment regimens in 149 patients with pemphigus in Tuscany (Italy): a 12-year hospital-based study","volume":"13","author":"Quintarelli L","year":"2022","unstructured":"Quintarelli L, Coi A, Maglie R, et al.. Clinical patterns, survival, comorbidities, and treatment regimens in 149 patients with pemphigus in Tuscany (Italy): a 12-year hospital-based study. Front Immunol. 2022, 13:895490. 10.3389\/fimmu.2022.895490","journal-title":"Front Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/life11070621","article-title":"Evolving mechanisms in the pathophysiology of pemphigus vulgaris: a review emphasizing the role of desmoglein 3 in regulating p53 and the Yes-associated protein","volume":"11","author":"Rehman A","year":"2021","unstructured":"Rehman A, Huang Y, Wan H. Evolving mechanisms in the pathophysiology of pemphigus vulgaris: a review emphasizing the role of desmoglein 3 in regulating p53 and the Yes-associated protein. Life (Basel). 2021, 11:10.3390\/life11070621","journal-title":"Life (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1201a37","article-title":"Pemphigus vulgaris: Present and future therapeutic strategies","volume":"12","author":"Didona D","year":"2022","unstructured":"Didona D, Paolino G, Di Zenzo G, Didona B, Pampena R, Di Nicola MR, Mercuri SR. Pemphigus vulgaris: Present and future therapeutic strategies. Dermatol Pract Concept. 2022, 12:e2022037. 10.5826\/dpc.1201a37","journal-title":"Dermatol Pract Concept"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0975-962X (11)60028-2","article-title":"Pemphigus vulgaris\u2014a case report and detailed review of literature","volume":"2","author":"Hasan S","year":"2011","unstructured":"Hasan S, Ahmed S, Khan NI, Tarannum F. Pemphigus vulgaris\u2014a case report and detailed review of literature. Indian J Dent. 2011, 2:113-9. 10.1016\/S0975-962X (11)60028-2","journal-title":"Indian J Dent"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7897\/2230-8407.100369","article-title":"Pemphigus vulgaris: an update on etiopathogenesis, clinical manifestations, diagnosis and treatment modalities","volume":"10","author":"Hasan S","year":"2019","unstructured":"Hasan S, Ahmed S, Kiran R. Pemphigus vulgaris: an update on etiopathogenesis, clinical manifestations, diagnosis and treatment modalities. Int Res J Pharm. 2019, 10:1-6. 10.7897\/2230-8407.100369","journal-title":"Int Res J Pharm"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4103\/jispcd.JISPCD_421_18","article-title":"Removable prosthetic treatment in oral pemphigus vulgaris: report of three cases","volume":"9","author":"Corsalini M","year":"2019","unstructured":"Corsalini M, Rapone B, Di Venere D, Petruzzi M. Removable prosthetic treatment in oral pemphigus vulgaris: report of three cases. J Int Soc Prev Community Dent. 2019, 9:423-6. 10.4103\/jispcd.JISPCD_421_18","journal-title":"J Int Soc Prev Community Dent"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11226858","article-title":"Childhood pemphigus vulgaris during COVID-19 outbreak successfully treated with prednisone and azathioprine: a case report and literature review","volume":"11","author":"Vezzoli P","year":"2022","unstructured":"Vezzoli P, Parietti M, Carugno A, et al.. Childhood pemphigus vulgaris during COVID-19 outbreak successfully treated with prednisone and azathioprine: a case report and literature review. J Clin Med. 2022, 11:10.3390\/jcm11226858","journal-title":"J Clin Med"},{"key":"ref9","article-title":"Rituximab therapy in severe juvenile pemphigus vulgaris","volume":"80","author":"Mamelak AJ","year":"2007","unstructured":"Mamelak AJ, Eid MP, Cohen BA, Anhalt GJ. Rituximab therapy in severe juvenile pemphigus vulgaris. Cutis. 2007, 80:335-40.","journal-title":"Cutis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2012.01730.x","article-title":"Pediatric pemphigus vulgaris: durable treatment responses achieved with prednisone and mycophenolate mofetil (MMF)","volume":"30","author":"Baratta A","year":"2013","unstructured":"Baratta A, Camarillo D, Papa C, Treat JR, Payne AS, Rozenber SS, Yan AC. Pediatric pemphigus vulgaris: durable treatment responses achieved with prednisone and mycophenolate mofetil (MMF). Pediatr Dermatol. 2013, 30:240-4. 10.1111\/j.1525-1470.2012.01730.x","journal-title":"Pediatr Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4103\/ijdd.ijdd_11_21","article-title":"Rituximab in childhood pemphigus vulgaris: a case report","volume":"7","author":"Kulkarni V","year":"2021","unstructured":"Kulkarni V, Potdar S, Shirol P. Rituximab in childhood pemphigus vulgaris: a case report. Indian J Drugs Dermatol. 2021, 7:88-90. 10.4103\/ijdd.ijdd_11_21","journal-title":"Indian J Drugs Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5005\/jp-journals-10005-1434","article-title":"Childhood occurrence of pemphigus","volume":"10","author":"U Patil R","year":"2017","unstructured":"U Patil R, T Anegundi R, R Gujjar K, Indushekar KR. Childhood occurrence of pemphigus. Int J Clin Pediatr Dent. 2017, 10:196-200. 10.5005\/jp-journals-10005-1434","journal-title":"Int J Clin Pediatr Dent"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.04744.x","article-title":"Rituximab in severe pemphigus","volume":"1173","author":"Schmidt E","year":"2009","unstructured":"Schmidt E, Goebeler M, Zillikens D. Rituximab in severe pemphigus. Ann N Y Acad Sci. 2009, 1173:683-91. 10.1111\/j.1749-6632.2009.04744.x","journal-title":"Ann N Y Acad Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.IJD_199_17","article-title":"Shifting focus in the therapeutics of immunobullous disease","volume":"62","author":"De A","year":"2017","unstructured":"De A, Ansari A, Sharma N, Sarda A. Shifting focus in the therapeutics of immunobullous disease. Indian J Dermatol. 2017, 62:282-90. 10.4103\/ijd.IJD_199_17","journal-title":"Indian J Dermatol"},{"key":"ref15","unstructured":"PRISMA transparent reporting of systematic review and meta-analysis. (2021). http.\/\/www.prismastatement.org\/PRISMAStatement\/PRISMAStatement.aspx."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell DF","year":"2008","unstructured":"Murrell DF, Dick S, Ahmed AR, et al.. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008, 58:1043-6. 10.1016\/j.jaad.2008.01.012","journal-title":"J Am Acad Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.46658\/JBIMES-20-08","article-title":"Systematic reviews of etiology and risk","author":"Moola S","year":"2017","unstructured":"Moola S, Munn Z, Tufanaru C, et al.. Systematic reviews of etiology and risk. Joanna Briggs Institute Reviewer\u2019s Manual. The Joanna Briggs Institute, Adelaide, Australia; 2017. 217-69. 10.46658\/JBIMES-20-08"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/pde.13926","article-title":"Rituximab therapy in pediatric pemphigus patients: a retrospective analysis of five Turkish patients and review of the literature","volume":"36","author":"Bilgic-Temel A","year":"2019","unstructured":"Bilgic-Temel A, \u00d6zgen Z, Harman M, Kap\u0131c\u0131o\u011flu Y, Uzun S. Rituximab therapy in pediatric pemphigus patients: a retrospective analysis of five Turkish patients and review of the literature. Pediatr Dermatol. 2019, 36:646-50. 10.1111\/pde.13926","journal-title":"Pediatr Dermatol"},{"key":"ref20","article-title":"A case of pediatric pemphigus treated with rituximab: our experience","volume":"2","author":"Broshtilova V","year":"2019","unstructured":"Broshtilova V, Vassileva S. A case of pediatric pemphigus treated with rituximab: our experience. Asian J Res Dermatol Sci. 2019, 2:1-6.","journal-title":"Asian J Res Dermatol Sci"},{"key":"ref21","article-title":"Successful treatment of refractory childhood vesiculobullous disorders with rituximab: a study of five cases","volume":"17","author":"Buch JY","year":"2016","unstructured":"Buch JY, Raval RC. Successful treatment of refractory childhood vesiculobullous disorders with rituximab: a study of five cases. Indian J Paediatr Dermatol. 2016, 17:104-7.","journal-title":"Indian J Paediatr Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedneo.2013.08.008","article-title":"Oral ulcers as an initial presentation of juvenile pemphigus: a case report","volume":"57","author":"Chen IH","year":"2016","unstructured":"Chen IH, Mu SC, Tsai D, Chou YY, Wang LF, Wang LJ. Oral ulcers as an initial presentation of juvenile pemphigus: a case report. Pediatr Neonatol. 2016, 57:338-42. 10.1016\/j.pedneo.2013.08.008","journal-title":"Pediatr Neonatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1159\/000287254","article-title":"Rituximab in childhood pemphigus vulgaris: a long-term follow-up case and review of the literature","volume":"221","author":"Fuertes I","year":"2010","unstructured":"Fuertes I, Guilabert A, Mascar\u00f3 JM Jr, Iranzo P. Rituximab in childhood pemphigus vulgaris: a long-term follow-up case and review of the literature. Dermatology. 2010, 221:13-6. 10.1159\/000287254","journal-title":"Dermatology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.4103\/ijdvl.IJDVL_1078_14","article-title":"Low-dose rituximab as an adjuvant therapy in pemphigus","volume":"83","author":"Gupta J","year":"2017","unstructured":"Gupta J, Raval RC, Shah AN, et al.. Low-dose rituximab as an adjuvant therapy in pemphigus. Indian J Dermatol Venereol Leprol. 2017, 83:317-25. 10.4103\/ijdvl.IJDVL_1078_14","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04391.x","article-title":"Efficacy and safety of rituximab treatment in Indian pemphigus patients","volume":"27","author":"Kanwar AJ","year":"2013","unstructured":"Kanwar AJ, Tsuruta D, Vinay K, Koga H, Ishii N, Dainichi T, Hashimoto T. Efficacy and safety of rituximab treatment in Indian pemphigus patients. J Eur Acad Dermatol Venereol. 2013, 27:e17-23. 10.1111\/j.1468-3083.2011.04391.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.100587","article-title":"Childhood pemphigus vulgaris successfully treated with rituximab","volume":"78","author":"Kanwar AJ","year":"2012","unstructured":"Kanwar AJ, Sawatkar GU, Vinay K, Hashimoto T. Childhood pemphigus vulgaris successfully treated with rituximab. Indian J Dermatol Venereol Leprol. 2012, 78:632-4. 10.4103\/0378-6323.100587","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1788702","article-title":"Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment: a case series of 13 patients","volume":"33","author":"Kianfar N","year":"2022","unstructured":"Kianfar N, Dasdar S, Mahmoudi H, Tavakolpour S, Balighi K, Daneshpazhooh M. Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment: a case series of 13 patients. J Dermatolog Treat. 2022, 33:869-74. 10.1080\/09546634.2020.1788702","journal-title":"J Dermatolog Treat"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12744","article-title":"Rituximab therapy for childhood pemphigus vulgaris","volume":"33","author":"Kincaid L","year":"2016","unstructured":"Kincaid L, Weinstein M. Rituximab therapy for childhood pemphigus vulgaris. Pediatr Dermatol. 2016, 33:e61-4. 10.1111\/pde.12744","journal-title":"Pediatr Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2005.00118.x","article-title":"Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab)","volume":"22","author":"Kong HH","year":"2005","unstructured":"Kong HH, Prose NS, Ware RE, Hall RP 3rd. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab). Pediatr Dermatol. 2005, 22:461-4. 10.1111\/j.1525-1470.2005.00118.x","journal-title":"Pediatr Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12684","article-title":"Retrospective study on autoimmune blistering disease in paediatric patients","volume":"32","author":"Kong YL","year":"2015","unstructured":"Kong YL, Lim YL, Chandran NS. Retrospective study on autoimmune blistering disease in paediatric patients. Pediatr Dermatol. 2015, 32:845-52. 10.1111\/pde.12684","journal-title":"Pediatr Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.IJD_366_16","article-title":"Autoimmune bullous disease in childhood","volume":"62","author":"Salman A","year":"2017","unstructured":"Salman A, Tekin B, Yucelten D. Autoimmune bullous disease in childhood. Indian J Dermatol. 2017, 62:440. 10.4103\/ijd.IJD_366_16","journal-title":"Indian J Dermatol"},{"key":"ref32","doi-asserted-by":"crossref","DOI":"10.5005\/jp-journals-10052-0085","article-title":"Juvenile pemphigus vulgaris","volume":"4","author":"Srivastava A","year":"2017","unstructured":"Srivastava A, Poornima G, Balaji P, Krishnan S. Juvenile pemphigus vulgaris. Int J Prev Clin Dent Res. 2017, 4:72-5.","journal-title":"Int J Prev Clin Dent Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1177\/00099228221140801","article-title":"Successful treatment of recalcitrant pediatric pemphigus vulgaris with rituximab","volume":"62","author":"Santiago-V\u00e1zquez M","year":"2023","unstructured":"Santiago-V\u00e1zquez M, Gonz\u00e1lez-Molina VJ, Rodriguez-Ramos FM, Col\u00f3n-Fontanez F, Carrasquillo OY. Successful treatment of recalcitrant pediatric pemphigus vulgaris with rituximab. Clin Pediatr (Phila). 2023, 62:541-7. 10.1177\/00099228221140801","journal-title":"Clin Pediatr (Phila)"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.05.071","article-title":"Successful use of rituximab in the treatment of\u00a0childhood and juvenile pemphigus","volume":"71","author":"Vinay K","year":"2014","unstructured":"Vinay K, Kanwar AJ, Sawatkar GU, Dogra S, Ishii N, Hashimoto T. Successful use of rituximab in the treatment of\u00a0childhood and juvenile pemphigus. J Am Acad Dermatol. 2014, 71:669-75. 10.1016\/j.jaad.2014.05.071","journal-title":"J Am Acad Dermatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2011.01514.x","article-title":"Analysis of current therapy and clinical outcome in childhood pemphigus vulgaris","volume":"28","author":"Mabrouk D","year":"2011","unstructured":"Mabrouk D, Ahmed AR. Analysis of current therapy and clinical outcome in childhood pemphigus vulgaris. Pediatr Dermatol. 2011, 28:485-93. 10.1111\/j.1525-1470.2011.01514.x","journal-title":"Pediatr Dermatol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly P","year":"2017","unstructured":"Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al.. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017, 389:2031-40. 10.1016\/S0140-6736(17)30070-3","journal-title":"Lancet"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2015.1024651","article-title":"Rituximab by subcutaneous route","volume":"8","author":"Solal-Celigny P","year":"2015","unstructured":"Solal-Celigny P. Rituximab by subcutaneous route. Expert Rev Hematol. 2015, 8:147-53. 10.1586\/17474086.2015.1024651","journal-title":"Expert Rev Hematol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01974","article-title":"Serological diagnosis of autoimmune bullous skin diseases","volume":"10","author":"Saschenbrecker S","year":"2019","unstructured":"Saschenbrecker S, Karl I, Komorowski L, et al.. Serological diagnosis of autoimmune bullous skin diseases. Front Immunol. 2019, 10:1974. 10.3389\/fimmu.2019.01974","journal-title":"Front Immunol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.4103\/ccd.ccd_461_18","article-title":"Childhood pemphigus vulgaris: report of two cases with emphasis on diagnostic approach","volume":"9","author":"Surya V","year":"2018","unstructured":"Surya V, Kumar P, Gupta S, Urs AB. Childhood pemphigus vulgaris: report of two cases with emphasis on diagnostic approach. Contemp Clin Dent. 2018, 9:S373-6. 10.4103\/ccd.ccd_461_18","journal-title":"Contemp Clin Dent"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/247160-rituximab-in-childhood-and-juvenile-pemphigus-vulgaris-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T08:45:19Z","timestamp":1713170719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/247160-rituximab-in-childhood-and-juvenile-pemphigus-vulgaris-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.58288","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,15]]}}}